



Screening KPI data summary factsheets

November 2018 – Issue 5

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland

About PHE screening

Screening identifies apparently healthy people who may be at increased risk of a disease or condition, enabling earlier treatment or informed decisions. National population screening programmes are implemented in the NHS on the advice of the UK National Screening Committee (UK NSC), which makes independent, evidence-based recommendations to ministers in the 4 UK countries. PHE advises the government and the NHS so England has safe, high quality screening programmes that reflect the best available evidence and the UK NSC recommendations. PHE also develops standards and provides specific services that help the local NHS implement and run screening services consistently across the country.

www.gov.uk/phe/screening Twitter: @PHE_Screening Blog: phescreening.blog.gov.uk For queries relating to this document, please contact: phe.screeninghelpdesk@nhs.net



© Crown copyright 2018

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published November 2018 PHE publications gateway number: 2018627



PHE supports the UN Sustainable Development Goals



Introduction

This high-level report presents the key performance indicator (KPI) data for all 11 national screening programmes. The NHS Screening Programmes selected the KPIs to define consistent performance measures for a selection of public health priorities. The KPIs give a high level overview of the quality of screening programmes at key points on the screening pathway. They contribute to the quality assurance of screening programmes but are not, in themselves, sufficient to quality assure or performance manage screening services.

Screening KPIs are contained within the Section 7a agreements between the Department of Health (DH) and NHS England and in the Public Health Outcomes Framework (PHOF).

This report will focus on the most recent data collected with national comparisons to quarterly performance since 2015 to 2016 where available.

Please note this factsheet is not re-issued if the corresponding KPI data is updated.

Further information

This report should be read in conjunction with the full KPI datasets for Q4 2017 to 2018 and Q1 2018 to 2019, and the KPI reporting data definitions for 2018 to 2019.

For all information about KPIs, including submission dates, templates and previous quarterly and annual data publications, please see our national data reporting page. Information about screening standards and service specifications are available for each programme.

Please contact the screening helpdesk if you would like further information on screening KPIs: phe.screeninghelpdesk@nhs.net.

Index of KPIs

Antenatal and newborn


KPI code	KPI name
<u>ID1</u>	Antenatal infectious disease screening – HIV coverage
<u>ID2</u>	Antenatal infectious disease screening – timely assessment of women with hepatitis B
<u>ID3</u>	Antenatal infectious disease screening – hepatitis B coverage
<u>ID4</u>	Antenatal infectious disease screening – syphilis coverage
<u>FA1</u>	Fetal anomaly screening – completion of laboratory request forms
<u>FA2</u>	Fetal anomaly screening – ultrasound coverage
FA3	Fetal anomaly screening – coverage for Down's, Edwards' and Patau's syndromes
<u>ST1</u>	Antenatal sickle cell and thalassaemia screening – coverage
<u>ST2</u>	Antenatal sickle cell and thalassaemia screening – timeliness of test
<u>ST3</u>	Antenatal sickle cell and thalassaemia screening – completion of FOQ
<u>ST4a</u>	Antenatal sickle cell and thalassaemia screening – timely offer of prenatal diagnosis (PND) to women at risk of having an affected infant
<u>ST4b</u>	Antenatal sickle cell and thalassaemia screening – timely offer of prenatal diagnosis (PND) to couples at risk of having an affected infant
<u>NB1</u>	Newborn blood spot screening – coverage (CCG responsibility at birth)
<u>NB2</u>	Newborn blood spot screening – avoidable repeat tests
<u>NB4</u>	Newborn blood spot screening – coverage (movers in)
<u>NH1</u>	Newborn hearing screening – coverage
<u>NH2</u>	Newborn hearing – time from screening outcome to attendance at an audiological assessment appointment
<u>NP1</u>	Newborn and infant physical examination – coverage (newborn)
<u>NP2</u>	Newborn and infant physical examination – timely assessment of developmental dysplasia of the hip (DDH)

Index of KPIs

Young person and adult

KPI code	KPI name
DE1	Diabetic eye screening – uptake of routine digital screening event
DE2	Diabetic eye screening – results issued within 3 weeks of routine digital screening
DE3	Diabetic eye screening – timely assessment for R3A screen positive
<u>AA2</u>	Abdominal aortic aneurysm screening – coverage of initial screen
<u>AA3</u>	Abdominal aortic aneurysm screening – coverage of annual surveillance screen
<u>AA4</u>	Abdominal aortic aneurysm screening - coverage of quarterly surveillance screen
BCS1	Bowel cancer screening – uptake
BCS2	Bowel cancer screening – coverage
<u>BS1</u>	Breast screening – uptake
<u>BS2</u>	Breast screening – screening round length
<u>CS1</u>	Cervical screening – coverage (under 50)
<u>CS2</u>	Cervical screening – coverage (50 and above)


Infectious diseases in pregnancy (IDPS) programme KPI ID1: HIV coverage



National trend data




*Thresholds changed in 2016 to 2017





KPI ID1 description

The proportion of pregnant women eligible for HIV screening for whom a confirmed screening result is available at the day of report

Infectious diseases in pregnancy (IDPS) programme KPI ID2: Timely assessment of women with hepatitis B










KPI ID2 description

The proportion of pregnant women who are hepatitis B positive attending for specialist assessment within 6 weeks of the positive result being reported to maternity services

Infectious diseases in pregnancy (IDPS) programme KPI ID3: Hepatitis B coverage









KPI ID3 description


The proportion of pregnant women eligible for hepatitis B screening for whom a confirmed screening result is available at the day of report

Infectious diseases in pregnancy (IDPS) programme

KPI ID4: Syphilis coverage








KPI ID4 description


The proportion of pregnant women eligible for syphilis screening for whom a confirmed screening result is available at the day of report


Back to index

Fetal anomaly screening programme (FASP)

KPI FA1: Completion of laboratory request forms









KPI FA1 description


The proportion of laboratory request forms including complete data prior to screening analysis, submitted to the laboratory within the recommended timeframe of 10⁺⁰ to 20⁺⁰ weeks' gestation

Fetal anomaly screening programme (FASP)

KPI FA2: Ultrasound coverage







KPI FA2 description

The proportion of pregnant women eligible for fetal anomaly ultrasound screening who are tested leading to a conclusive result within the designated timescale

Fetal anomaly screening programme (FASP)

KPI FA3: Coverage for Down's, Edwards' and Patau's syndromes




FA3 is a new KPI introduced in 2018 to 2019. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required. After this time PHE Screening will review the data with the aim of publishing it nationally from the following year


KPI FA3 description


The proportion of pregnant women eligible for first trimester combined screening for T21 and T18/T13 for whom a conclusive screening result is available at the day of report

Sickle cell and thalassaemia (SCT) screening programme

KPI ST1: Coverage










KPI ST1 description

The proportion of pregnant women eligible for antenatal sickle cell and thalassaemia screening for whom a screening result is available at the day of report

Sickle cell and thalassaemia (SCT) screening programme KPI ST2: Timeliness of test










KPI ST2 description

The proportion of women having antenatal sickle cell and thalassaemia screening for whom a screening result is available by 10 weeks + 0 days gestation

Sickle cell and thalassaemia (SCT) screening programme KPI ST3: Completion of FOQ







KPI ST3 description

The proportion of antenatal sickle cell and thalassaemia samples submitted to the laboratory accompanied by a completed FOQ

Sickle cell and thalassaemia (SCT) screening programme

KPI ST4a: Timely offer of prenatal diagnosis (PND) to women at risk of having an affected infant



ST4a is a new KPI introduced in 2018 to 2019. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required. After this time PHE Screening will review the data with the aim of publishing it from the following year

KPI ST4a description

The proportion of at-risk women offered PND by 12 weeks + 0 days gestation

Sickle cell and thalassaemia (SCT) screening programme

KPI ST4b: Timely offer of prenatal diagnosis (PND) to couples at risk of having an affected infant





ST4b is a new KPI introduced in 2018 to 2019. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required. After this time PHE Screening will review the data with the aim of publishing it from the following year

KPI ST4b description


The proportion of at risk couples offered PND by 12 weeks + 0 days gestation

Newborn blood spot (NBS) screening programme KPI NB1: Coverage (CCG responsibility at birth)





*Achieveable threshold changed in 2017 to 2018




KPI NB1 description


The proportion of babies registered within the clinical commissioning group (CCG) both at birth and on the last day of the reporting period who are eligible for newborn blood spot (NBS) screening and have a conclusive result recorded on the child health information system (CHIS) at less than or equal to 17 days of age

Reported by: CCG


Newborn blood spot (NBS) screening programme

KPI NB2: Avoidable repeat tests





*Achievable threshold changed in 2017 to 2018




KPI NB2 description


The proportion of first blood spot samples that require repeating due to an avoidable failure in the sampling process

Newborn blood spot (NBS) screening programme KPI NB4: Coverage (movers in)





*Achievable threshold changed in 2017 to 2018




KPI NB4 description


The proportion of all babies eligible for newborn blood spot (NBS) screening who have changed responsible CCG in the first year of life or have moved in from another UK country or abroad and have a conclusive result recorded on the CHIS at less than or equal to 21 calendar days of notifying the CHRD of movement in

Reported by: CCG


Newborn hearing screening programme (NHSP)

KPI NH1: Coverage





*Threshold changed in 2016 to 2017, and 2018 to 2019




KPI NH1 description


The proportion of babies eligible for newborn hearing screening for whom the screening process is complete by 4 weeks corrected age (hospital programmes: well babies, NICU babies) or by 5 weeks corrected age (community programmes: well babies) Reported by: Local NHSP site


Back to index

Newborn hearing screening programme (NHSP)

KPI NH2: Time from screening outcome to attendance at an audiological assessment appointment








KPI NH2 description


The proportion of babies with a no clear response result in 1 or both ears or other result that require an immediate onward referral for audiological assessment who receive audiological assessment within the required timescale


Reported by: Local NHSP site

Newborn and infant physical examination (NIPE) screening programme

KPI NP1: Coverage (newborn)









KPI NP1 description


The proportion of babies eligible for the newborn physical examination who are tested for all 4 components (3 components in female infants) of the newborn examination within 72 hours of birth

Newborn and infant physical examination (NIPE) screening programme

KPI NP2: Timely assessment of developmental dysplasia of the hip









KPI NP2 description

The proportion of babies who have a positive screening test on newborn physical examination and undergo assessment by specialist hip ultrasound within 2 weeks of age

Diabetic eye screening (DES) programme


KPI DE1: Uptake of routine digital screening event







*Thresholds changed in 2017 to 2018




KPI DE1 description


The proportion of those offered routine digital screening who attend a digital screening event where images are captured


Reported by: Local DES service

Diabetic eye screening (DES) programme

KPI DE2: Results issued within 3 weeks of routine digital screening, digital surveillance or slit lamp biomicroscopy








KPI DE2 description


The proportion of subjects attending for diabetic eye screening, digital surveillance or slit lamp biomicroscopy to whom results were issued within 3 weeks of the screening event


Reported by: Local DES service

Diabetic eye screening (DES) programme

KPI DE3: Timely assessment for R3A screen positive







KPI DE3 description

The proportion of screen positive subjects with referred proliferative (R3A) diabetic retinopathy attending for assessment within 6 weeks of their screening event from all diabetic eye screening pathways

Reported by: Local DES service

Abdominal aortic aneurysm (AAA) screening programme


KPI AA2: Coverage of initial screen




2016 to 2017 was the first year of data publication for AA2. AA2 is an annual indicator; quarterly figures are aggregated from Q1 to the current quarter

The performance thresholds for AA2 increase on a quarterly basis in order to best reflect the nature of the local screening service call to screening

National performance of AA2 in Q1 was above the achievable threshold. 31 out of 39 screening providers met the acceptable threshold of 18%






KPI AA2 description


The proportion of men eligible for abdominal aortic aneurysm screening who are conclusively tested

Reported by: Local AAA screening service

Abdominal aortic aneurysm (AAA) screening programme KPI AA3: Coverage of annual surveillance screen









KPI AA3 description


The proportion of annual surveillance appointments due where there is a conclusive test within 6 weeks of the due date

Reported by: Local AAA screening service

Abdominal aortic aneurysm (AAA) screening programme KPI AA4: Coverage of quarterly surveillance screen









KPI AA4 description


The proportion of quarterly surveillance appointments due where there is a conclusive test within 4 weeks of the due date

Reported by: Local AAA screening service

Bowel cancer screening programme (BCSP) KPI BCS1: Uptake








KPI BCS1 description

The proportion of eligible men and women aged 60 to 74 years invited to participate in bowel cancer screening who adequately participate


Reported by: Local screening centre (also by CCG in the data publication)

Bowel cancer screening programme (BCSP) KPI BCS2: Coverage











KPI BCS2 description


The proportion of eligible men and women aged 60 to 74 years invited for screening who have had an adequate faecal occult blood test (FOBt) screening result in the previous 30 months

Reported by: Local authority

Breast screening programme (BSP) KPI BS1: Uptake







KPI BS1 description

The proportion of eligible women invited who attend for screening

Reported by: Local screening service


Breast screening programme (BSP) KPI BS2: Screening round length



2017 to 2018 was the first year of data publication for BS2

National performance of BS2 in Q1 was 87.5%, below the acceptable threshold

56 out of 79 screening providers reached the acceptable threshold; no providers met the achievable threshold





KPI BS2 description

The proportion of eligible women whose date of first offered appointment is within 36 months of their previous screen. Women being screened for the first time will not be included in screening round length statistics

Reported by: Local screening service


Back to index

Cervical screening programme (CSP) KPI CS1: Coverage (under 50 years)



National trend data





KPI CS1 description


The proportion of women in the resident population eligible for cervical screening aged 25 to 49 years at end of period reported who were screened adequately within the previous 3.5 years


Reported by: CCG

Back to index

Cervical screening programme (CSP) KPI CS2: Coverage (50 years and above)







KPI CS2 description

The proportion of women in the resident population eligible for cervical screening aged 50 to 64 years at end of reported period who were screened adequately within the previous 5.5 years

Reported by: CCG